Arecor Therapeutics PLC Expansion of specialty hospital collaboration (8679Y)
2024年1月8日 - 4:00PM
RNSを含む英国規制内ニュース (英語)
TIDMAREC
RNS Number : 8679Y
Arecor Therapeutics PLC
08 January 2024
Arecor Therapeutics plc
("Arecor" or the "Group")
ARECOR ANNOUNCES EXPANSION OF EXISTING SPECIALTY HOSPITAL
FORMULATION COLLABORATION
Cambridge, UK, 8 January 2024: Arecor Therapeutics plc (AIM:
AREC), the biopharmaceutical group advancing today's therapies to
enable healthier lives, today announces the expansion of its
ongoing, exclusive formulation study collaboration with the
pharmaceutical division of one of the world's largest chemicals
marketing and pharmaceuticals companies, which focuses on the
development and commercialisation of speciality drugs .
The collaboration, in which Arecor is using its proprietary
formulation technology platform, Arestat(TM), to develop a
differentiated, ready-to-use liquid formulation of its partner's
product, AT351, has progressed significantly since it began in
November 2022. Arecor will now undertake additional in-house
activities to accelerate the development programme, enabling rapid
progress towards its partner's Pre-Investigational New Drug
(Pre-IND) meeting with the US FDA.
The partner will provide additional funds for Arecor's expanded
development work and continues to have an option to acquire the
rights to the new proprietary formulation and associated
Intellectual Property under Arecor's technology licensing model to
further develop and commercialise the product.
Sarah Howell, Chief Executive Officer of Arecor, said: "The
rapid progress of this collaboration and expansion of the
development project illustrate the value that our proprietary
technology platform, Arestat(TM), and our experience in the
specialty hospital field, can bring to our partners and the
development of differentiated medicines to improve patient
outcomes."
This announcement contains inside information for the purposes
of the retained UK version of the EU Market Abuse Regulation (EU)
596/2014 ("UK MAR").
-ENDS-
For more information, please contact:
Arecor Therapeutics plc www.arecor.com
Dr Sarah Howell, Chief Executive Tel: +44 (0) 1223 426060
Officer Email: info@arecor.com
Susan Lowther, Chief Financial Officer Tel: +44 (0) 1223 426060
Email: info@arecor.com
Mo Noonan, Communications Tel: +44 (0) 7876 444977
Email: mo.noonan@arecor.com
Panmure Gordon (UK) Limited (NOMAD Tel: +44 (0) 20 7886 2500
and Broker)
Freddy Crossley, Emma Earl (Corporate
Finance)
Rupert Dearden (Corporate Broking)
ICR Consilium
Chris Gardner, David Daley, Lindsey Tel: +44 (0) 20 3709 5700
Neville Email: arecor@consilium-comms.com
Notes to Editors
About Arecor
Arecor Therapeutics plc is a globally focused biopharmaceutical
company transforming patient care by bringing innovative medicines
to market through the enhancement of existing therapeutic products.
By applying our innovative proprietary technology platform,
Arestat(TM), we are developing an internal portfolio of proprietary
products in diabetes and other indications, as well as working with
leading pharmaceutical and biotechnology companies to deliver
therapeutic products. The Arestat(TM) platform is supported by an
extensive patent portfolio.
For further details please see our website, www.arecor.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCFLFETLRIDIIS
(END) Dow Jones Newswires
January 08, 2024 02:00 ET (07:00 GMT)
Arecor Therapeutics (LSE:AREC)
過去 株価チャート
から 4 2024 まで 5 2024
Arecor Therapeutics (LSE:AREC)
過去 株価チャート
から 5 2023 まで 5 2024